Human p95HER2 Stable Cell Line-Ba/F3

The Human p95HER2 Stable Cell Line-Ba/F3 is a genetically engineered cell line that stably expresses the p95HER2 truncated isoform of the human epidermal growth factor receptor 2 (HER2/ERBB2) in the murine Ba/F3 hematopoietic progenitor background. p95HER2, also referred to as the truncated HER2 or HER2 carboxyl-terminal fragment, arises from proteolytic shedding of the full-length HER2 extracellular domain or through alternative translation initiation, resulting in a membrane-anchored, constitutively active kinase that lacks the ligand-binding region. This truncated form retains the transmembrane domain and the intact intracellular tyrosine kinase domain, enabling ligand-independent dimerization and persistent downstream signaling through the PI3K/AKT and MAPK pathways. The Ba/F3 cell line, originally an interleukin-3 (IL-3)-dependent pro-B cell line widely used in oncology research, provides a clean genetic background with minimal endogenous receptor tyrosine kinase expression. When engineered to express p95HER2, these cells acquire IL-3-independent growth, allowing functional selection and stable maintenance of the transgene.

The Human p95HER2 Stable Cell Line-Ba/F3 serves as a valuable tool for preclinical drug discovery and mechanistic studies targeting the truncated HER2 receptor. Researchers can use this cell line to evaluate the efficacy and selectivity of novel small molecule tyrosine kinase inhibitors, antibody-drug conjugates, and other therapeutic modalities designed to block p95HER2 signaling or degrade the truncated receptor. The IL-3-independent growth phenotype provides a convenient readout for cell proliferation assays, making it suitable for high-throughput screening campaigns aimed at identifying compounds that selectively inhibit p95HER2-driven growth. Additionally, this model enables investigation of resistance mechanisms that emerge in HER2-positive cancers following treatment with trastuzumab or lapatinib, as p95HER2 expression is known to confer intrinsic resistance to these agents. The cell line can also be employed in combination therapy studies to identify synergistic drug pairs that overcome p95HER2-mediated resistance, as well as in downstream signaling analysis to map the specific phosphorylation events and transcriptional programs activated by the truncated receptor.